UA101348C2 - 1,2,4-оксадиазольные соединения для лечения аутоиммунных заболеваний - Google Patents
1,2,4-оксадиазольные соединения для лечения аутоиммунных заболеванийInfo
- Publication number
- UA101348C2 UA101348C2 UAA201009201A UAA201009201A UA101348C2 UA 101348 C2 UA101348 C2 UA 101348C2 UA A201009201 A UAA201009201 A UA A201009201A UA A201009201 A UAA201009201 A UA A201009201A UA 101348 C2 UA101348 C2 UA 101348C2
- Authority
- UA
- Ukraine
- Prior art keywords
- heading
- treatment
- formula
- pharmaceutically acceptable
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Данное изобретение касается новых производных оксадиазола формулы (I)(I)или их фармацевтически приемлемых солей.Соединения формулы (I) и их фармацевтически приемлемые соли полезны при лечении состояний или расстройств, которые опосредуются через S1P1-рецептор.В частности, соединения формулы (I) и их фармацевтически приемлемые соли полезны при лечении рассеянного склероза, аутоиммунных заболеваний, хронических воспалительных расстройств, астмы, воспалительной нейропатии, артрита, трансплантации, болезни Крона, язвенного колита, красной волчанки, псориаза, реперфузионного для ишемий повреждения, твердых опухолей и метастазов опухоли, расстройств, связанных с ангиогенезом, сосудистых заболеваний, болевых состояний, острых вирусных заболеваний, состояний воспаленного кишечника, инсулинозависимых и инсулинонезависимых диабетов.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0725102.8A GB0725102D0 (en) | 2007-12-21 | 2007-12-21 | Compounds |
PCT/EP2008/067972 WO2009080730A1 (en) | 2007-12-21 | 2008-12-19 | 1, 2, 4 -oxadiazole compounds for the treatment of autoimmune diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
UA101348C2 true UA101348C2 (ru) | 2013-03-25 |
Family
ID=39048652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201009201A UA101348C2 (ru) | 2007-12-21 | 2008-12-19 | 1,2,4-оксадиазольные соединения для лечения аутоиммунных заболеваний |
Country Status (19)
Country | Link |
---|---|
US (1) | US20100273770A1 (ru) |
EP (1) | EP2220077A1 (ru) |
JP (1) | JP2011506572A (ru) |
KR (1) | KR20100108567A (ru) |
CN (1) | CN101945865A (ru) |
AU (1) | AU2008339993A1 (ru) |
BR (1) | BRPI0821696A2 (ru) |
CA (1) | CA2710055A1 (ru) |
CO (1) | CO6290674A2 (ru) |
CR (1) | CR11576A (ru) |
DO (1) | DOP2010000193A (ru) |
EA (1) | EA017669B1 (ru) |
GB (1) | GB0725102D0 (ru) |
IL (1) | IL206277A0 (ru) |
MA (1) | MA31923B1 (ru) |
NZ (1) | NZ585995A (ru) |
UA (1) | UA101348C2 (ru) |
WO (1) | WO2009080730A1 (ru) |
ZA (1) | ZA201003965B (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
GB0725101D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
GB0807910D0 (en) | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
WO2012019076A1 (en) * | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury |
EP2511275A1 (en) * | 2011-04-12 | 2012-10-17 | Bioprojet | Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists |
US9040711B2 (en) | 2012-07-02 | 2015-05-26 | Monsanto Technology Llc | Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles |
CN107827837B (zh) * | 2017-11-21 | 2021-09-24 | 苏州朗科生物技术股份有限公司 | 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1670463A2 (en) * | 2003-10-01 | 2006-06-21 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
US7605171B2 (en) * | 2003-12-17 | 2009-10-20 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
WO2006047195A2 (en) * | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
BRPI0612028A2 (pt) * | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
WO2007116866A1 (ja) * | 2006-04-03 | 2007-10-18 | Astellas Pharma Inc. | ヘテロ化合物 |
PE20091339A1 (es) * | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
-
2007
- 2007-12-21 GB GBGB0725102.8A patent/GB0725102D0/en not_active Ceased
-
2008
- 2008-12-19 NZ NZ585995A patent/NZ585995A/xx not_active IP Right Cessation
- 2008-12-19 BR BRPI0821696-7A patent/BRPI0821696A2/pt not_active IP Right Cessation
- 2008-12-19 AU AU2008339993A patent/AU2008339993A1/en not_active Abandoned
- 2008-12-19 CN CN2008801273545A patent/CN101945865A/zh active Pending
- 2008-12-19 JP JP2010538744A patent/JP2011506572A/ja active Pending
- 2008-12-19 UA UAA201009201A patent/UA101348C2/ru unknown
- 2008-12-19 US US12/747,198 patent/US20100273770A1/en not_active Abandoned
- 2008-12-19 EA EA201070783A patent/EA017669B1/ru not_active IP Right Cessation
- 2008-12-19 EP EP08863729A patent/EP2220077A1/en not_active Withdrawn
- 2008-12-19 CA CA2710055A patent/CA2710055A1/en not_active Abandoned
- 2008-12-19 KR KR1020107016168A patent/KR20100108567A/ko not_active Application Discontinuation
- 2008-12-19 WO PCT/EP2008/067972 patent/WO2009080730A1/en active Application Filing
-
2010
- 2010-06-03 ZA ZA2010/03965A patent/ZA201003965B/en unknown
- 2010-06-10 IL IL206277A patent/IL206277A0/en unknown
- 2010-06-16 MA MA32925A patent/MA31923B1/fr unknown
- 2010-06-21 CO CO10074469A patent/CO6290674A2/es not_active Application Discontinuation
- 2010-06-21 DO DO2010000193A patent/DOP2010000193A/es unknown
- 2010-07-21 CR CR11576A patent/CR11576A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BRPI0821696A2 (pt) | 2015-06-16 |
CO6290674A2 (es) | 2011-06-20 |
EA017669B1 (ru) | 2013-02-28 |
US20100273770A1 (en) | 2010-10-28 |
CR11576A (es) | 2010-09-03 |
IL206277A0 (en) | 2010-12-30 |
ZA201003965B (en) | 2011-03-30 |
NZ585995A (en) | 2012-12-21 |
AU2008339993A1 (en) | 2009-07-02 |
WO2009080730A1 (en) | 2009-07-02 |
EP2220077A1 (en) | 2010-08-25 |
JP2011506572A (ja) | 2011-03-03 |
KR20100108567A (ko) | 2010-10-07 |
DOP2010000193A (es) | 2010-08-15 |
EA201070783A1 (ru) | 2010-12-30 |
GB0725102D0 (en) | 2008-01-30 |
CN101945865A (zh) | 2011-01-12 |
CA2710055A1 (en) | 2009-07-02 |
MA31923B1 (fr) | 2010-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA101348C2 (ru) | 1,2,4-оксадиазольные соединения для лечения аутоиммунных заболеваний | |
WO2012149186A3 (en) | Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use | |
WO2014049610A3 (en) | Peptides as gip, glp-1 and glucagon receptors triple-agonist | |
MX2014015158A (es) | Derivados de piridinona y piridazinona. | |
MX2008013212A (es) | 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r. | |
CL2008000198A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis. | |
CL2011001060A1 (es) | Compuestos derivados de 4-[3-{3-(1,2,4-oxadiazol-5-il)-1h-pirazol-1-il}-metil]-piridina, 3-[3-{3-(1,2,4-oxadiazol-5-il)-1h-pirazol-1-il}-metil)-fenilo, 3-[3-{3-(1,2,4-oxadiazol-5-il)-1h-pirazol-1-il}-metil)-fenilo; procedimiento de preparacion; composicion farmaceutica; utiles para tratar enfermedades cancerosas o tumorales. | |
PH12015500860A1 (en) | 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders | |
WO2007113558A8 (en) | Quinazolinone derivatives having b-raf inhibitory activity | |
MX2009004908A (es) | Compuestos quimicos. | |
JP2013518110A (ja) | 疼痛および他の適応症の治療用の医薬組成物 | |
PE20081878A1 (es) | Compuestos derivados de 1-(4-hidroxifenil sustituido)-4-ol-indazol | |
MY154462A (en) | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | |
MX2010009922A (es) | Activadores de piridazinona glucocinasa. | |
MY181731A (en) | Azole benzene derivative | |
MX2009004561A (es) | Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor. | |
MX2012006734A (es) | Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas. | |
PH12014502448A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
JP2016510326A5 (ru) | ||
JP2016508506A5 (ru) | ||
ZA202201828B (en) | Therapeutic fusion proteins | |
UY27689A1 (es) | Nuevos derivados de tiazol como antagonistas del receptor npy | |
JP2011528334A5 (ru) | ||
MX2009007889A (es) | Derivados de 3-cinnolincarboxamida y su uso para el tratamiento del cancer. | |
CA3046196A1 (en) | Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases |